Effectiveness and Tolerability of Tapentadol Prolonged Release Compared With Prior Opioid Therapy for the Management of Severe, Chronic Osteoarthritis Pain

BACKGROUND: Tapentadol prolonged release (PR; 100–250 mg twice daily) has been efficacious and well tolerated for managing moderate-to-severe, chronic osteoarthritis hip or knee pain in phase 3 studies with washout of previous analgesic treatment. OBJECTIVE: The objective of this study was to evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Steigerwald, Ilona, Schenk, Michael, Lahne, Uwe, Gebuhr, Peter, Falke, Dietmar, Hoggart, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2013
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751342/
https://www.ncbi.nlm.nih.gov/pubmed/23912473
http://dx.doi.org/10.1007/s40261-013-0102-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751342/
https://www.ncbi.nlm.nih.gov/pubmed/23912473
http://dx.doi.org/10.1007/s40261-013-0102-0

Ejemplares similares